of Veterinary Medicine. ©1999 AgBioForum. ECONOMICS OF RECOMBINANT BOVINE SOMATOTROPIN ON U.S. DAIRY FARMS

has been very rapidly adopted by the commercial dairy industry. It has been shown in repeated studies to be safe for cows and to be both effective and profitable if used in adequately managed dairies. It has been widely affirmed as safe for consumers of dairy products. The economic value of rBST is exerted by increasing the production of existing cows. The prinicpal cash costs for using this technology are the cost of the product and the additional feed needed to produce the milk, with some additional labor or capital costs on some dairies. Under typical conditions, the use of PosilacÒ in adequately managed dairy herds returns well over 50 % profit over the expenses at typical prices for milk and feed. By increasing production in existing cows, the technology spreads fixed costs over more production, increasing the margin and profits for the farm. The use of rBS is generally scale neutral and has a positive environmental impact by reducing the amount of manure produced per gallon of milk. Key words: PosilacÒ; BST; dairy; economics; biotechnology. Posilacâ, Monsanto’s genetically engineered version of bovine s matotropin (rBST), was approved for use in lactating dairy cows in the U.S. in February, 1994. In addition, 25 other countries hav